19 Our provisional view, on which we would welcome comments, is that the appraisal is likely to require evidence on
     
 
i
 clinical outcomes relative to no treatment and/or best existing treatment for the condition in question, including undesirable side-effects; and (for chronic conditions) effects of stopping treatment;
 
ii
 estimated impact on quality and (where appropriate) length of life;
 
iii
 estimated average health improvement per treatment initiated (derived from (i) and (ii)), expressed in terms of standard measures for combining life years and quality of life;
 
iv
 net NHS costs associated with this health gain;
 
v
 (where appropriate) any associated government-funded Personal Social Services costs and savings;
 
vi
 any significant differences in (i) to (v) between patient/population subgroups;
 
vii
 other dimensions not picked up in previous steps which are relevant to the appraisal;
 
viii
 expected total impact on NHS resources (including manpower resources).
   
  A wider range of costs and benefits may be relevant in particular circumstances.
   
20 Further detail of the sort of information that might be needed for assessment submissions, is at Annex C. These proposals will be reviewed in the light of the response to consultation and a set of detailed information requirements and methodological standards for the evaluation of health interventions will be published as soon as possible. This guidance will be updated from time to time by NICE in the light of experience and of wider developments in health technology assessment.